From this point of view, stocks are broadly recovering from their most oversold condition since March of last year -- and the release of the energy stored up then persisted at near-full strength for three months.
Top performing sectors have been basic materials and retailers. The latter is the most important because it's the most surprising to most people - and because it's been my top recommendations in the past month through SPDR Retail (NYSE: XRT). The good news was reinforced this week with a report on February sales that shocked the pessimists. On a day when the broad market rose only 0.4%, the XRT jumped 1.9%. Teen retailer Abercrombie & Fitch Co. (NYSE: ANF) leapt 14.5% to within an eyelash of its one-year high, and many companies that supply stores, like my recommended game maker Hasbro, Inc (NYSE: HAS), jumped to new highs as well. You can never underestimate Americans' love for shopping, no matter what their condition.
I said back then that public companies outperformed because they didn't just sit on their hands and watch their world collapse. They adapted. They laid off workers. They closed plants. They got smaller and leaner and tougher. They used the magic of operating leverage to make great profits on smaller revenue bases. And that's why 2009 turned into such a rout for bears.
Now look at the retail report that was published on Thursday, and what do you see? Retailers knew that they faced a tough year if they just kept doing what they had always done, so they adapted. They closed underperforming stores. They cut employees' hours. They got more productivity out of remaining workers. They cut their inventories. They stopped discounting. They pushed more of the sales pipeline burden onto their wholesalers. In a word, they adapted.
One of the more remarkable reports was turned in by Abercrombie & Fitch, which many retail experts had written off as out of touch with current teenagers who were snubbing the look of ritualistic logos and preppy sensuality. Analysts expected ANF to post a 6.9% decline in same-store sales, and instead they came up with a whopping 5% increase. Ken Perkins, president of Retail Metrics, told reporters: "Retailers have really done a great job of limiting their inventories, so they weren't stuck with a lot of stuff that they had to drastically mark down."
Of course one reason sales looked good was that they were being compared to levels of a year ago during the worst of the recession. And sober-sided analysts at Moody's told clients that they remained unconvinced that retailers' results were sustainable. But when you consider that malls on the east coast were closed, snowed in for half a week, and yet shopping centers as a group still posted a year-over-year 3.7% increase in traffic - the best since 2007 - it just has to catch your eye.
I've been mentioning that discounters were faring best, and that certainly was the case in the market on Thursday. Ross Stores, Inc. (NASDAQ: ROST), which I highlighted earlier in the week, jumped another 3.35% to a new all-time high. And Amazon.com, Inc. (NASDAQ: AMZN), which had been in a funk, rose 2.1% and finally edged above its 50-day average for the first time in more than two months. According to Markethistory.com data, when in the current technical configuration (above its 200-day and 50-day averages on March 4), AMZN has risen in four of the past four instances by an average of 26% over the next 10 weeks. (Caution: Its recent large five-day gain will limit near-term upside.)
Bottom line: While it's true that the consumer isn't dead yet despite stagnant wages, non-existent job growth, falling home values and declining credit levels, the real story here is that retailers did a great job of adjusting their businesses to meet the challenge.
Blow-ups and Buyouts
I always keep a close watch on new highs and new lows every day, because those stocks are on the vanguard of winning and losing sectors.
One of those new lows last week illustrates why I hardly ever recommend small biotech stocks. Medivation (NASDAQ: MDVN) was shot out of the sky after its Alzheimer's disease therapy was found to have no effect in late-stage clinical trials compared to a placebo. What kills you about biotech stocks is that their stories are always so awesome that they're hard to resist. MDVN had its Dimebon drug validated via a partnership with drug giant Pfizer, Inc. (NYSE: PFE), and in a previous trial some experts said it had produced better results than any of the drugs already approved for treating Alzheimer's. The New York Times reported that as recently as two weeks ago, an Alzheimer's researcher had said of Dimebon, ''The clinical data is by far and away superior to anything that's ever been shown before.''
Of course that researcher just happened to be a Medivation consultant, that prior trial was done in Russia under somewhat suspicious circumstances, and not even Pfizer was exactly sure how the drug worked. And yet MDVN shares had steadily risen three-fold since December 2008. It's back there now after falling 67% on Wednesday and another 7% on Friday, mostly in a gap from which there was no escape.
On the plus side of the ledger this week were more deals. Southwest Water Co. (NASDAQ: SWWC) jumped 46% after it said it would go private, and enterprise networking products maker Novell, Inc (NASDAQ: NOVL) rose 28% after receiving a buyout bid from a private equity fund.
What I want you to notice in both cases is that the companies were both in boring, low-growth fields and frankly have undistinguished product lines and earnings records. But they are reliable cash generators, and super-cheap, and that makes them attractive to the right buyers. That is almost exactly the scenario that I was describing on Tuesday night in reference to a recently recommended storage device maker Quantum Corporation (NYSE: QTM). If you want to read more about QTM's prospects from an enthusiastic owner, check out this article at Seeking Alpha by veteran value investor Joe Feshbach.
StrataGem Focus: Cognizant Technology Solutions
Every month I launch a new set of 10 stock picks made by my proprietary StrataGem model, and our new group for March got off to a good start this week, rising 5.2% as a group, about double the broad market.
For those of you who have never seen my service, a quick explanation: StrataGem is a stock-ranking system that I developed nine years ago in the middle of the tech bear market. In the prior ten years, investors had grown enamored with fundamental analysts and a mere upgrade of a stock could send it flying. But in 2000 the cover started to come off the ball, and underneath the brokerages' glitzy exterior turned out to be a rotten network of good old boys bulling unworthy companies for the benefit of their investment-banking clients. Shocker, I know -- who'd a thunk.
StrataGem is a "statistical arbitrage" system that uses a set of mathematical formulas to try to find the fastest growing companies with the lowest valuations that are likely to rise in the next one to six months with the lowest volatility. After all stocks are ranked from high to low, the system then determines which are in sectors, market capitalization groups or valuation groups that are the most likely to rise over the next one to six months.
So the stocks we present as the top 10 should be among the fastest growing, least expensive and least volatile in the market. It's obviously not right every month, but usually wins in eight out of twelve months. Last year the set of ten were up, as a group, in nine months (results here). The bulk of the gains came in March and April, though July, October and December were very good too. It's notoriously hard to determine how well a "stat-arb" system will do in any given month. Last year was a great example: March saw the group rise 13.2%, but the prior month was down 5% and the first week of that month was horrific. So you just have to mechanically buy every month if you follow this path. Members decide for themselves how much of their personal portfolios to devote to StrataGem; depending on their situation, around 15% to 25% can be appropriate.
The largest member of the new March StrataGem list is Cognizant Technology Solutions Corp. (NASDAQ: CTSH), which is a leading offshore provider of information technology services to big companies. It's based in the United States, but is considered by most to be an Indian company since most of its operations are there.
It has been a major beneficiary of globalization, as revenue has risen 50% on average over the past five years -- a stunning number. Analysts applaud its consultative approach to solving clients' problems and ability to increase its share of clients' business by delivering consistent cost savings.
In the fourth quarter of 2009, the company reported 20% revenue growth over the previous year and a 9% boost over the previous quarter. Jefferies & Co. analysts noted that the company's 20% operating margin remains a "substantial buffer to any unexpected cost pressures," which in English means that if its input costs rise it can still hit earnings estimates by cutting costs.
The Jefferies team is looking for earnings per share to grow 13.5% this year to $2.02 before expanding another 16% in 2011. This is one of the most successful companies in the world over the past decade, and emerging from a three-year consolidation. CTSH has been on our list twice in the past year, recommended at $30 and $38.60. Now it's $48.15. The model likes it long and the daily chart looks good. Still a buy on pullbacks.
The Week in Review
Monday: The ISM Manufacturing Index continued to indicate month-over-month growth for the manufacturing sector. The index came in at 56.5 versus the 57.5 consensus estimate ant the 58.4 prior reading. Any level over 50 indicates expansion.
New orders remain strong but moderated somewhat by falling to 59.5 -- ending a string of 60-plus readings. Backlogs were a big area of growth, expanding 5 points to 61. The narrative here is the production managers are still cautious, waiting until the last minute to hire new works and expand production to meet new orders. As a result, backlogs are growing. Eventually, for fear of losing out to competitors, new workers will be hired.
Tuesday: Motor vehicle sales were remarkably resilient in February despite a bout of severe winter weather and the ongoing accelerator pedal debacle at Toyota. Sales came in at a 7.6 million annualized rate. This was just below the consensus estimate and prior month's figure of 7.9 million.
Wednesday: The ISM Non-Manufacturing Index, which measures the activity in the all-important services sector, jumped to 53 in February -- signaling solid month-to-month growth for the majority of the U.S. economy. This was well ahead of the consensus estimate of 51 and the period month's 50.5 result. New services orders increased to 55 -- the best rate of month-to-month growth seen since August 2007.
Thursday: Retailers reported impressive sales figures for February despite severe winter weather. In fact, Retail Metrics noted that its same-store sales index rose 4.1% in February against a 3% forecast. This is the biggest monthly gain since November 2007. Overall, 82% of retailers beat sales expectations, and this helped push retail stocks up in a big way.
It's also important to note that factory orders increased in January, while weekly initial jobless claims dropped slightly. But offsetting the good news was a dour pending existing home sales report. This is yet another data point showing that housing succumbed to a serious drop in activity in the wake of the expiration of the now extended first-time homebuyer tax credit.
Friday: Investors reacted favorably to a better-than-expected February jobs report. And by "better" I mean less bad than pessimists had feared. Employers still cut 36,000 jobs, but the unemployment rate stayed at 9.7% despite the severe winter weather seen during the month. Philippa Dunne of the Liscio Report had this to say about the numbers:
"All in all, it looks like the labor market continues to stabilize, but it's not really turning around. We think it would be a mistake to write off this month's employment numbers as nothing but a weather report; there's very little evidence for that. The labor market continues to behave in a fashion typical of post-financial-crisis recessions, a sharp fall followed by extended flatness."
The Week Ahead
Monday: A couple of Treasury bill auctions.
Tuesday: A few more Treasury auctions. Brazilian energy giant Petroleo Brasileiro SA (NYSE ADR: PBR) reports earnings.
Wednesday: U.S. Treasury Budget and a 10-year note auction. Watch the yields on 10-years to see if long-term interest rates are headed higher as investors prepare for the end of the Federal Reserve's direct mortgage purchases.
Thursday: An update on the U.S. trade balance and weekly initial jobless claims will be reported.
Friday: Reports on retail sales, consumer sentiment, and business inventories. Cytori Therapeutics (Nasdaq: CYTX) reports earnings at 7 a.m. ET.
[Editor's Note : As this bear-market analysis demonstrates, Money Morning Contributing Writer Jon D. Markman has a unique view of both the world economy and the global financial markets. With uncertainty the watchword and volatility the norm in today's markets, low-risk/high-profit investments will be tougher than ever to find.
It will take a seasoned guide to uncover those opportunities.
Markman is that guide.
In the face of what's been the toughest market for investors since the Great Depression, it's time to sweep away the uncertainty and eradicate the worry. That's why investors subscribe to Markman's Strategic Advantage newsletter every week: He can see opportunity when other investors are blinded by worry.
Subscribe to Strategic Advantage and hire Markman to be your guide. For more information,please click here.]
News and Related Story Links:
Retailing Stocks and Stats Suggest the U.S. Stock Market Rally is For Real
Is it Time to Buy Monsanto?
Biotech Churns Out Big Returns in Bull and Bear Markets